

Applicant : John T. Isaacs et al.  
Serial No. : 09/588,921  
Filed : June 7, 2000  
Page : 5

Attorney's Docket No.: 07265-149003

13  
31. (Amended) The composition of claim 19, wherein the therapeutic drug is a compound belonging to the group of thapsigargins which have been derivatized with a moiety containing a primary amino group, the peptide is His-Ser-Ser-Lys-Leu-Gln (SEQ ID NO:7), and the linker is selected from the group consisting of unsubstituted or alkyl-, aryl-, halo-, alkoxy-, alkkenyl-, amido-, or amino-substituted CO-(CH=CH)<sub>n1</sub>-(CH<sub>2</sub>)<sub>n2</sub>-Ar-NH<sub>2</sub>, CO-(CH<sub>2</sub>)<sub>n2</sub>-(CH=CH)<sub>n1</sub>-Ar-NH<sub>2</sub>, CO-(CH<sub>2</sub>)<sub>n2</sub>-(CH=CH)<sub>n1</sub>-CO-NH-Ar-NH<sub>2</sub> and CO-(CH=CH)<sub>n1</sub>-(CH<sub>2</sub>)<sub>n2</sub>-CO-NH-Ar-NH<sub>2</sub> wherein n1 and n2 are from 0 to 5, Ar is any substituted or unsubstituted aryl group, and attachment of NH<sub>2</sub> to Ar is in a ortho, meta or para position with respect to the remainder of the linker.

B9  
cnt